and FSH (12-14), the increasing quality of available antisera has permitted the specific determination of these hormones in small serum or plasma samples. The introduction of monoclonal antibodies has especially stimulated the development of two-site immunemetric assays with superior specificity. Several commercial assay systems for FSH and LH are available (15, 16), usually based on the use of radioactive reagents.
the pituitary gland secretes both hormones in a pulsatile fashion (3), frequent, sequential LH measurements are used to assess ovarian function [e.g., in sports medicine (4) and during stimulation of follicles by gonadoliberin (5)]. Assessment of pubertal disorders (6, 7) and of the inhibition of ovarian function during breast cancer therapy (8) requires reliable procedures capable of measuring very low concentrations of both hormones.
Since the first applications of immunoassay to LH (9-li) and FSH (12) (13) (14) , the increasing quality of available antisera has permitted the specific determination of these hormones in small serum or plasma samples. The introduction of monoclonal antibodies has especially stimulated the development of two-site immunemetric assays with superior specificity. Several commercial assay systems for FSH and LH are available (15, 16), usually based on the use of radioactive reagents.
Here, we present two new enzyme-linked immunosorbent assays (ELISAs) . Because of the specificity of the combined monoclonal antibodies, both assays are highly specific and accurate. The assays permit assessment of samples with low and high concentrations of the analytes without interferences by antibody-binding substances, including heterophilic antibodies. Both assays are available for automated systems and manual application. We present results from a multicenter evaluation and a comparative study.
MaterIals and Methods

Samples. The multicenter evaluation
was performed in 10 laboratories. FSH and LH were measured in serum from -1100 subjects. The samples (serum or plasma) were obtained from local patients and control subjects, subdivided into eight groups: children, men, nonpregnant women [follicular phase, midcycle (less than two days before ovulation), luteal phase, and postinenopausal], pregnant women, and women during stimulation in in-vitro fertilization programs.
FSH and LH enzyme immunoassays. All determinations were done with Enzymun-Test FSH#{174} and Enzymun-Test#{174} LH (Boehringer Mannheim GmbH, Mannheim, F.R.G.). Each of the participating laboratories received the following reagents. To test the specificity of the assays described, we added various amounts of commercially available (Boehringer  Mannheim) preparations of pituitary hormones, their a-and /3-subunits, and choriogonadotropin (hCG) to human sera having no detectable concentrations of FSH or UI. These preparations, which had been calibrated against the appropriate IRPs, were h-UI (contamination with FSH <0.6%); h-FSH (contamination with UI <1%); human thyrotropin (h-TSH; contamination with FSH <1%, with UI <4%); hCG (contamination with both FSH and UI <1%); h-UI/3 (<1% h-UIa); hCG/3 (<0.1% hCGa); h-TSHa (<1% h-TSH/3); and h-UIa (<2% h-UI/3). The highest quantities used in the tests are indicated later (see Table 2 ).
Evaluation procedure. Besides making a practical evaluation of the reagents sets of the manufacturer, all participating laboratories measured FSH and UI concentrations in all samples, using their standard inhouse techniques. Some of the participating laboratories used more than one set of reagents. These techniques included five competitive radioimmunoassays and six twosite sandwich assays, as described in Table 1 . All participants performed these assays according to the manufacturer's instructions.
All results were expressed in international units, based on reference preparations 78/549 for FSH and 68/40 for LH. 
Cakulation
of data. All participating laboratories supplied one of the authors (A.C.K.) with the raw data (absorbances, absorptivities) generated by the automated instruments.
From these data, the results for standards and for the concentrations of gonadotropins in human sera were calculated by standard computerized programs developed according to described procedures (17) .
Statistics.
We compared the methods by the maincomponent procedure for linear regression described by Passing and Bablock (18) , because this nonparametric method does not require special assumptions about the distribution of the results.
Results
Assay Performance
Reproducibility of standards.
The the 1st IS is equivalent to 2.92 mt.units of the 2nd IRP.  For LH, 1 mt.unit of the 2nd IS is equivalent to 0.90 mt. unit of the 1st IRP. These differences will be important when the recommended reference preparations are changed.
Linearity. Figure 3 .
High-dose "hook" effects. Adding large quantities of purified FSH or LH to human sera showed that concentrations as great as 4000 mt. unitsfL for FSH and 3000 int. units/L for UI caused no high-dose "hook" effects.
Interferences.
Interference with the determinations was tested by diluting sera with high FSH and LH concentrations with hemolytic, lipemic, icteric, uremic, dysproteinemic, or rheumatoid samples. No evidence was found for interference by any of these factors.
The effects of heterophilic antibodies were studied by using blood samples obtained after screening 10000 human serum samples for non-LHJnon-FSH antibodybinding substances with a special ELISA designed to detect murmne antibodies. Of 16 sera that were positive for these antibodies, four (13) caused falsely increased FSH. (or LH) values when assayed with the original reagents. Addition of monoclonal mouse-IgG (} polymerized according to a proprietary procedure (patent pending), prevented this interference. Because the reagents used in the study described here had been so modified, no interference from heterophilic antibodies was seen.
The final concentrations of the additives used during this evaluation did not interfere with the quantitative recovery of added FSH or LH. showed no systematic differences between the results of competitive assays and two-site noncompetitive assays. Again, the lack of agreement between users of identical reagents can be seen (fluoroinimunoassay 1 and immunoradiometric assay 1).
ReferenceValues
Because the results in the participating laboratories were comparable, we tried to define reference values for FSH and LII concentrations in serum. A summary of the results for normal subjects is given in Table 4 . The criteria used by the participating laboratories to decide whether to include the data from a particular individual were based on information they had on the absence of abnormalities.
The midcycle samples were collected within 48 h of ovulation, which was detected by daily sonographic evaluation.
These values must be considered as guidelines, and each individual laboratory must still compile its own reference values.
DiscussIon
In the first part of this paper, we described a multi- The results for precision and accuracy We did not try to separate the results according to the instruments used. The reagents can be used manually, but fully automated analyses can be performed on the ES600. In the evaluation, the reproducibility of the results from laboratories using this equipment was slightly better than from those working manually or semi-automatically with the ES22. Comparing the results of the Enzymun-Test FSII and Enzymun-Test UI with other commercially available reagents requires special attention. In general, correlations between the two new assays and other kits were good; in only one series of LII determinations in one laboratory was the correlation coefficient <0.93. Because this systematic discrepancy was observed almost exclusively in the comparison between the EnzymunTest UI and this set of reagents, the discrepancy may well be caused by this particular combination of reagents.
The other participating laboratories had occasional discrepancies in the results for UI, mainly those laboratories using competitive immunoassays. These differences could not be attributed to laboratory errors, as shown by repeating the assays with both sets of reagents. The most likely explanation for such differences in assay results is cross-reactivity with the hCG present in some of the samples and the heterogeneity of the glycoprotemns analyzed. Researchers discussing true values for the concentration of gonadotropins in serum usually consider bioassay results the closest to the truth. Recent findings, however, indicate that substances can be found in human plasma that interfere with the commonly used in vitro bioassay for LH (25) . Thus, which method gives results closest to reality for the determination of gonadotropins in small blood samples is still uncertain.
